Company profile for Liminatus Pharma

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

The focus behind the incorporation of our company is to develop (from clinical trials and FDA approvals through to manufacturing and sales) solid tumor cancer CAR-Ts that treat metastatic GI cancers by using GCC CAR-T therapies. To achieve this goal, we have obtained a license for all GCC CAR-T-related patents and know-hows from Targeted Diagnostics & Therapeutics, Inc. (TDT), and our merger with Viral Gene, Inc., a company...
The focus behind the incorporation of our company is to develop (from clinical trials and FDA approvals through to manufacturing and sales) solid tumor cancer CAR-Ts that treat metastatic GI cancers by using GCC CAR-T therapies. To achieve this goal, we have obtained a license for all GCC CAR-T-related patents and know-hows from Targeted Diagnostics & Therapeutics, Inc. (TDT), and our merger with Viral Gene, Inc., a company that develops virus-based cancer immunotherapeutics, will help position us as a leader in GCC CAR-T therapeutics.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
6 Centerpointe Drive Suite 625 La Palma, CA 90623
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Clinical Outsourcing

Clinical Outsourcing

Not Confirmed

envelop Contact Supplier

Clinical Outsourcing

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2026/02/17/3239319/0/en/Liminatus-Pharma-Inc-Announces-Pricing-of-4-0-Million-Public-Offering.html

GLOBENEWSWIRE
17 Feb 2026

https://www.globenewswire.com/news-release/2025/10/30/3177589/0/en/Liminatus-Pharma-Inc-NASDAQ-LIMN-Signs-MOU-with-Capital-Trust-Group-for-USD-30-Million-Equity-Investment-via-an-earn-out-mechanism-and-Future-Strategic-Cooperation.html

GLOBENEWSWIRE
30 Oct 2025

https://www.globenewswire.com/news-release/2025/07/28/3122367/0/en/Liminatus-Pharma-Inc-to-Launch-American-BNB-Strategy-Subsidiary-and-Target-Up-To-500-Million-Fund-for-BNB-Investment-as-Part-of-Crypto-Market-Initiative.html

GLOBENEWSWIRE
28 Jul 2025

https://www.globenewswire.com/news-release/2025/07/25/3121787/0/en/Liminatus-Pharma-Inc-Evaluates-Formation-of-Digital-Asset-Investment-Vehicle-Targeting-Up-To-500-Million-in-Capital-Strategies.html

GLOBENEWSWIRE
25 Jul 2025

https://www.globenewswire.com/news-release/2025/07/24/3121080/0/en/Liminatus-Pharma-Inc-Takes-Next-Step-in-Evaluating-Digital-Asset-Linked-Capital-Strategy.html

GLOBENEWSWIRE
24 Jul 2025

https://www.globenewswire.com/news-release/2025/07/22/3119752/0/en/Liminatus-Pharma-Inc-Initiates-Strategic-Review-of-Blockchain-Integrated-Treasury-Strategy.html

GLOBENEWSWIRE
22 Jul 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty